Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C.
Velev M, et al. Among authors: laramas m.
Eur J Cancer. 2023 Mar;182:66-76. doi: 10.1016/j.ejca.2022.12.028. Epub 2023 Jan 13.
Eur J Cancer. 2023.
PMID: 36746010
Clinical Trial.